Dopaminergic control of TSH secretion in endogenous depression.
To evaluate whether the inhibitory control exerted by endogenous dopamine on thyroid-stimulating hormone (TSH) secretion is altered in patients with major depressive disorder, 11 depressed patients and 9 normal controls were tested with the dopaminergic receptor antagonist domperidone (10 or 20 mg i.v.). The administration of domperidone induced a significant increase in circulating TSH levels in the normal controls, but not in the depressed patients. These data excluded the possibility that the dopaminergic inhibition of TSH secretion is enhanced in depression. To establish whether domperidone failure was due to a reduced dopaminergic tone, domperidone was administered before stimulation of TSH secretion with thyrotropin-releasing hormone (TRH) (200 micrograms i.v.). The TSH response to TRH was significantly lower in the depressed than in the control subjects, regardless of domperidone priming. However, in both groups domperidone enhanced the TRH-induced TSH release by 50%. These data suggest that the dopaminergic control of TSH secretion is not altered in patients with endogenous depression and that a reduced capacity of the pituitary to secrete TSH might be responsible for the reduced TSH responsiveness to TRH and domperidone.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001921:Brain / Q000503:physiopathology*; D003866:Depressive Disorder / Q000503:physiopathology*; D004294:Domperidone; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011954:Receptors, Dopamine / Q000502:physiology*; D013972:Thyrotropin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone
D011954:Receptors, Dopamine; D004294:Domperidone; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin